Timogel ® vs timolol 0.5% ophthalmic solution: Efficacy, safety, and acceptance

European Journal of Ophthalmology

Volumn 22, Issue 1, 2011, Pages 28-33

  Rolle, Teresa ^a   Curto, Daniela ^a   Alovisi, Camilla ^a   Franzone, Mauro ^a   Brogliatti, Beatrice ^a   Grignolo, Federico M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Acceptance; Glaucoma; Preservative free; Safety; Timolol

Indexed keywords

EYE DROPS; PRESERVATIVE; TIMOGEL; TIMOLOL; UNCLASSIFIED DRUG;

ARTICLE; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; EYE BLOOD FLOW; EYE BURNING; EYE DISEASE; EYE STINGING; EYELID EDEMA; EYELID REDNESS; FOLLOW UP; FOREIGN BODY; FOREIGN BODY SENSATION; GEL; HEART RATE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MORNING DOSAGE; OCULAR DIASTOLIC PERFUSION PRESSURE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERFUSION PRESSURE; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIRMER TEST; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; GELS; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; QUESTIONNAIRES; TEARS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 81855184550     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000006     Document Type: Article

References (22)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-93.
2. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population: The Egna-Neumarkt Study. Ophthalmology 1998; 105: 209-15.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-7.
4. Kass MA, Heuer DK, Higginbotham EJ, et al, Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13, discussion 829-30.
5. Lichter PR, Musch DC, Gillespie BW, et al, CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-53.
6. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7: The relationship between control of intraocular pressure and visual field deterioration. Am J Oph-thalmol 2000; 130: 429-40.
7. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
8. Remis LL, Epstein DL. Treatment of glaucoma. Annu Rev Med 1984; 35: 195-205.
9. Shedden A, Laurence J, Tipping R, Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 2001; 23: 440-50.
10. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86: 418-23.
11. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17: 341-9.
12. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147: 725-35.
13. Uusitalo H, Niño J, Tahvanainen K, et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand 2005; 83: 723-8.
14. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240: 430-5.
15. European Glaucoma Society. Terminology and Guidelines 2003. Savona: Dogma, 2003; 51-65.
16. Peterson RC, Wolffsohn JS. Objective grading of the anterior eye. Optom Vis Sci 2009; 86: 273-8.
17. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerabil-ity of ophthalmic medications. Ophthalmology 1997; 104: 334-42.
18. Mayer H, von der Ohe N. Efficacy of a novel hydrogel formulation in human volunteers. Ophthalmologica 1996; 210: 101-3.
19. Baudouin C, Béchetoille A, Bron A, et al. Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma. J Fr Ophtalmol 2000; 23: 1057-64.
20. Rouland JF, Denis P, Béchetoille A, et al. Création dβun questionnaire spécifique évaluant la qualité de vie chez les patients glaucomateux: la generation des items. J Fr Ophtal-mol 2002; 25: 785-94.
21. Easty DL, Nemeth-Wasmer G, Vounatsos J P, et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006; 90: 574-8.
22. Beckers HJ, Schouten JS, Webers CA, van der Valk R, Hen-drikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1485-90.